Skip to main content

Table 1 Characteristics of the included studies

From: Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

Study (reference no.)

Year

Study design (NCT No.)

Interventions

Sex (male/female),Age (mean ± SD)

Baseline Migraine-days per month (mean ± SD)

Follow-up

Uwe Reuter [14]

2018

RCT phase3b, NCT03096834

erenumab 140 mg

Placebo

24/97,44.6 ± 10.5

22/103,44.2 ± 10.6

9.2 ± 2.6

9.3 ± 2.7

12w

David W Dodick [15]

2017

RCT phase 3, NCT02483585

erenumab 70 mg

Placebo

41/245,42 ± 11

44/247,42 ± 12

8.1 ± 2.7

8.4 ± 2.6

12w

Peter J. Goadsby [24]

2017

RCT phase 3, NCT02456740

erenumab 70 mg

Placebo

49/268,41.1 ± 11.3

45/274,41.3 ± 11.2

8.3 ± 2.5

8.2 ± 2.5

24w

Hong Sun [25]

2016

RCT phase 2, NCT01952574

erenumab 70 mg

Placebo

25/82, 42.6 ± 9.9

28/132,41.4 ± 10.0

8.6 ± 2.5

8.8 ± 2.7

12w

David W Dodick [26]

2014

RCT phase 2, NCT01772524

Eptinezumab 1000 mg

Placebo

14/67,38.6 ± 10.8

16/66,39.0 ± 9.6

8.4 ± 2.1

8.8 ± 2.7

12w

David W. Dodick [16]

2018

RCT phase 3, NCT02629861

Fremanezumab 225 mg

Placebo

46/244,42.9 ± 12.7

47/247, 41.3 ± 12.0

8.9 ± 2.6

9.1 ± 2.7

12w

Marcelo E Bigal [27]

2015

RCT phase 2b, NCT02025556

Fremanezumab 225 mg

Placebo

9/87,40.8 ± 12.4

12/92,42.0 ± 11.6

11.5 ± 1.9

11.5 ± 2.24

12w

Vladimir Skljarevski# [28]

2018

RCT phase 2b, NCT02163993

Galcanezumab 120 mg

Placebo

42/231,40.6 ± 11.9

28/109,39.5 ± 12.1

6.7 ± 2.6

6.6 ± 2.7

12w

Vladimir Skljarevski [18]

2017

RCT Phase 3, NCT02614196

galcanezumab 120 mg

Placebo

34/197,40.9 ± 11.2

68/393,42.3 ± 11.3

9.07 ± 2.9

9.2 ± 3.0

24w

Virginia L. Stauffer [17]

2018

RCT phase 3, NCT02614183

galcanezumab 120 mg

Placebo

32/181,40.9 ± 11.9

71/362,41.3 ± 11.4

9.2 ± 3.1

9.1 ± 3.0

24w

David W Dodick [29]

2014

RCT phase 2, NCT01625988

galcanezumab 150 mg

Placebo

19/88,40.9 ± 11.4

14/96,41.9 ± 11.7

6.7 ± 2.4

7.0 ± 2.5

12w

  1. RCT Randomized controlled trial, SD Standard deviation. #The specific information can only be achieved in the total CGRP monoclonal antibodies treatment group